<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mazzucchelli S</submitter><funding>Ministero dell'Istruzione, dell'Università e della Ricerca</funding><funding>Ministero dell’Istruzione, dell’Università e della Ricerca</funding><pagination>220</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11210105</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment.&lt;h4>Methods&lt;/h4>PDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening.&lt;h4>Results&lt;/h4>Both PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they sh</pubmed_abstract><journal>Cancer cell international</journal><pubmed_title>Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.</pubmed_title><pmcid>PMC11210105</pmcid><funding_grant_id>PRIN 2017 ID2017EA2NR</funding_grant_id><pubmed_authors>Tagliaferri B</pubmed_authors><pubmed_authors>Corsi F</pubmed_authors><pubmed_authors>Camboni T</pubmed_authors><pubmed_authors>Signati L</pubmed_authors><pubmed_authors>Gasparini P</pubmed_authors><pubmed_authors>Pelucchi P</pubmed_authors><pubmed_authors>Castagnoli L</pubmed_authors><pubmed_authors>Bonizzi A</pubmed_authors><pubmed_authors>Franceschini A</pubmed_authors><pubmed_authors>Carelli S</pubmed_authors><pubmed_authors>Pupa SM</pubmed_authors><pubmed_authors>Messa L</pubmed_authors><pubmed_authors>Cifola I</pubmed_authors><pubmed_authors>Mangano E</pubmed_authors><pubmed_authors>Consolandi C</pubmed_authors><pubmed_authors>Villani L</pubmed_authors><pubmed_authors>Severgnini M</pubmed_authors><pubmed_authors>Mazzucchelli S</pubmed_authors><pubmed_authors>Cereda C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.</name><description>&lt;h4>Background&lt;/h4>A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment.&lt;h4>Methods&lt;/h4>PDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening.&lt;h4>Results&lt;/h4>Both PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they sh</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2026-07-15T03:04:53.434Z</modification><creation>2025-04-05T17:57:56.082Z</creation></dates><accession>S-EPMC11210105</accession><cross_references><pubmed>38926706</pubmed><doi>10.1186/s12935-024-03375-5</doi></cross_references></HashMap>